Continuation of gender-affirming hormones in transgender people starting puberty suppression in adolescence: a cohort study in the Netherlands
- PMID:36273487
- DOI: 10.1016/S2352-4642(22)00254-1
Continuation of gender-affirming hormones in transgender people starting puberty suppression in adolescence: a cohort study in the Netherlands
Abstract
Background: In the Netherlands, treatment with puberty suppression is available to transgender adolescents younger than age 18 years. When gender dysphoria persists testosterone or oestradiol can be added as gender-affirming hormones in young people who go on to transition. We investigated the proportion of people who continued gender-affirming hormone treatment at follow-up after having started puberty suppression and gender-affirming hormone treatment in adolescence.
Methods: In this cohort study, we used data from the Amsterdam Cohort of Gender dysphoria (ACOG), which included people who visited the gender identity clinic of the Amsterdam UMC, location Vrije Universiteit Medisch Centrum, Netherlands, for gender dysphoria. People with disorders of sex development were not included in the ACOG. We included people who started medical treatment in adolescence with a gonadotropin-releasing hormone agonist (GnRHa) to suppress puberty before the age of 18 years and used GnRHa for a minimum duration of 3 months before addition of gender-affirming hormones. We linked this data to a nationwide prescription registry supplied by Statistics Netherlands (Centraal Bureau voor de Statistiek) to check for a prescription for gender-affirming hormones at follow-up. The main outcome of this study was a prescription for gender-affirming hormones at the end of data collection (Dec 31, 2018). Data were analysed using Cox regression to identify possible determinants associated with a higher risk of stopping gender-affirming hormone treatment.
Findings: 720 people were included, of whom 220 (31%) were assigned male at birth and 500 (69%) were assigned female at birth. At the start of GnRHa treatment, the median age was 14·1 (IQR 13·0-16·3) years for people assigned male at birth and 16·0 (14·1-16·9) years for people assigned female at birth. Median age at end of data collection was 20·2 (17·9-24·8) years for people assigned male at birth and 19·2 (17·8-22·0) years for those assigned female at birth. 704 (98%) people who had started gender-affirming medical treatment in adolescence continued to use gender-affirming hormones at follow-up. Age at first visit, year of first visit, age and puberty stage at start of GnRHa treatment, age at start of gender-affirming hormone treatment, year of start of gender-affirming hormone treatment, and gonadectomy were not associated with discontinuing gender-affirming hormones.
Interpretation: Most participants who started gender-affirming hormones in adolescence continued this treatment into adulthood. The continuation of treatment is reassuring considering the worries that people who started treatment in adolescence might discontinue gender-affirming treatment.
Funding: None.
Copyright © 2022 Elsevier Ltd. All rights reserved.
Conflict of interest statement
Declaration of interests We declare no competing interests.
Similar articles
- Bone Mineral Density in Transgender Adolescents Treated With Puberty Suppression and Subsequent Gender-Affirming Hormones.van der Loos MATC, Vlot MC, Klink DT, Hannema SE, den Heijer M, Wiepjes CM.van der Loos MATC, et al.JAMA Pediatr. 2023 Dec 1;177(12):1332-1341. doi: 10.1001/jamapediatrics.2023.4588.JAMA Pediatr. 2023.PMID:37902760Free PMC article.
- Children and adolescents in the Amsterdam Cohort of Gender Dysphoria: trends in diagnostic- and treatment trajectories during the first 20 years of the Dutch Protocol.van der Loos MATC, Klink DT, Hannema SE, Bruinsma S, Steensma TD, Kreukels BPC, Cohen-Kettenis PT, de Vries ALC, den Heijer M, Wiepjes CM.van der Loos MATC, et al.J Sex Med. 2023 Feb 27;20(3):398-409. doi: 10.1093/jsxmed/qdac029.J Sex Med. 2023.PMID:36763938
- Defining the optimum strategy for identifying adults and children with coeliac disease: systematic review and economic modelling.Elwenspoek MM, Thom H, Sheppard AL, Keeney E, O'Donnell R, Jackson J, Roadevin C, Dawson S, Lane D, Stubbs J, Everitt H, Watson JC, Hay AD, Gillett P, Robins G, Jones HE, Mallett S, Whiting PF.Elwenspoek MM, et al.Health Technol Assess. 2022 Oct;26(44):1-310. doi: 10.3310/ZUCE8371.Health Technol Assess. 2022.PMID:36321689Free PMC article.
- Impact of residual disease as a prognostic factor for survival in women with advanced epithelial ovarian cancer after primary surgery.Bryant A, Hiu S, Kunonga PT, Gajjar K, Craig D, Vale L, Winter-Roach BA, Elattar A, Naik R.Bryant A, et al.Cochrane Database Syst Rev. 2022 Sep 26;9(9):CD015048. doi: 10.1002/14651858.CD015048.pub2.Cochrane Database Syst Rev. 2022.PMID:36161421Free PMC article.Review.
- Topical fluoride as a cause of dental fluorosis in children.Wong MCM, Zhang R, Luo BW, Glenny AM, Worthington HV, Lo ECM.Wong MCM, et al.Cochrane Database Syst Rev. 2024 Jun 20;6(6):CD007693. doi: 10.1002/14651858.CD007693.pub3.Cochrane Database Syst Rev. 2024.PMID:38899538Review.
Cited by
- Detransition needs further understanding, not controversy.MacKinnon KR, Expósito-Campos P, Gould WA.MacKinnon KR, et al.BMJ. 2023 Jun 14;381:e073584. doi: 10.1136/bmj-2022-073584.BMJ. 2023.PMID:37315956Free PMC article.
- Gender-Affirming Treatment of Gender Dysphoria in Youth: A Perfect Storm Environment for the Placebo Effect-The Implications for Research and Clinical Practice.Clayton A.Clayton A.Arch Sex Behav. 2023 Feb;52(2):483-494. doi: 10.1007/s10508-022-02472-8. Epub 2022 Nov 14.Arch Sex Behav. 2023.PMID:36376741Free PMC article.No abstract available.
- Puberty Blocker and Aging Impact on Testicular Cell States and Function.Murugesh V, Ritting M, Salem S, Aalam SMM, Garcia J, Chattha AJ, Zhao Y, Knapp DJ, Kalthur G, Granberg CF, Kannan N.Murugesh V, et al.bioRxiv [Preprint]. 2024 Mar 27:2024.03.23.586441. doi: 10.1101/2024.03.23.586441.bioRxiv. 2024.PMID:38585884Free PMC article.Preprint.
- Breastfeeding grief after chest masculinisation mastectomy and detransition: A case report with lessons about unanticipated harm.Gribble KD, Bewley S, Dahlen HG.Gribble KD, et al.Front Glob Womens Health. 2023 Feb 3;4:1073053. doi: 10.3389/fgwh.2023.1073053. eCollection 2023.Front Glob Womens Health. 2023.PMID:36817034Free PMC article.
- Adherence to Gender Affirming Hormone Therapy in Transgender Adolescents and Adults: A Retrospective Cohort Study.Gupta P, Patterson BC, Chu L, Gold S, Amos S, Yeung H, Goodman M, Tangpricha V.Gupta P, et al.J Clin Endocrinol Metab. 2023 Oct 18;108(11):e1236-e1244. doi: 10.1210/clinem/dgad306.J Clin Endocrinol Metab. 2023.PMID:37246711Free PMC article.
MeSH terms
Substances
Related information
LinkOut - more resources
Full Text Sources
Medical
Research Materials